CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
复制标题
DOI：
10.1007/s00262-021-03008-0
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
Babor F
中科院分区：
文献类型：
--
作者：
Reusing SB;Vallera DA;Manser AR;Vatrin T;Bhatia S;Felices M;Miller JS;Uhrberg M;Babor F
Similar to pediatric acute myeloid leukemia (AML) the subgroup of biphenotypic acute lymphoblastic leukemia (ALL) is a rare complex entity with adverse outcome, characterized by the surface expression of CD33. Despite novel and promising anti-CD19 targeted immunotherapies such as chimeric antigen receptor T cells and bispecific anti-CD19/CD3 antibodies, relapse and resistance remain a major challenge in about 30% to 60% of patients. To investigate the potential role of the fully humanized bispecific antibody CD16 × CD33 (BiKE) in children with CD33+ acute leukemia, we tested whether the reagent was able to boost NK cell effector functions against CD33+ AML and biphenotypic ALL blasts. Stimulation of primary NK cells from healthy volunteers with 16 × 33 BiKE led to increased cytotoxicity, degranulation and cytokine production against CD33+ cell lines. Moreover, BiKE treatment significantly increased degranulation, IFN-γ and TNF-α production against primary ALL and AML targets. Importantly, also NK cells from leukemic patients profited from restoration of effector functions by BiKE treatment, albeit to a lesser extent than NK cells from healthy donors. In particular, those patients with low perforin and granzyme expression showed compromised cytotoxic function even in the presence of BiKE. In patients with intrinsic NK cell deficiency, combination therapy of CD16xCD33 BiKE and allogeneic NK cells might thus be a promising therapeutic approach. Taken together, CD16xCD33 BiKE successfully increased NK cell effector functions against pediatric AML and biphenotypic ALL blasts and constitutes a promising new option for supporting maintenance therapy or “bridging” consolidation chemotherapy before hematopoietic stem cell transplantation. The online version contains supplementary material available at 10.1007/s00262-021-03008-0.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-15-2710
发表时间：
2016-07-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Vallera DA;Felices M;McElmurry R;McCullar V;Zhou X;Schmohl JU;Zhang B;Lenvik AJ;Panoskaltsis-Mortari A;Verneris MR;Tolar J;Cooley S;Weisdorf DJ;Blazar BR;Miller JS
通讯作者：
Miller JS
影响因子：
5.7
作者：
Gleason MK;Verneris MR;Todhunter DA;Zhang B;McCullar V;Zhou SX;Panoskaltsis-Mortari A;Weiner LM;Vallera DA;Miller JS
通讯作者：
Miller JS
影响因子：
7.3
作者：
Veluchamy JP;Kok N;van der Vliet HJ;Verheul HMW;de Gruijl TD;Spanholtz J
通讯作者：
Spanholtz J
影响因子：
10.1
作者：
Hejazi, Maryam;Manser, Angela R.;Uhrberg, Markus
通讯作者：
Uhrberg, Markus
DOI：
10.3390/antib9030034
发表时间：
2020-07-20
期刊：
Antibodies (Basel, Switzerland)
影响因子：
--
作者：
Zahavi D;Weiner L
通讯作者：
Weiner L